This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Uterine Corpus Leiomyosarcoma
Information about Uterine Corpus Leiomyosarcoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Uterine Corpus Leiomyosarcoma
Most recent studies have shown that Uterine Corpus Leiomyosarcoma shares some biological mechanisms with carcinoma, endometrial-polyp, fibroid-tumor, hemorrhage, leiomyosarcoma, lung-neoplasms, malignant-neoplasms, malignant-paraganglionic-neoplasm, metastatic-leiomyosarcoma, metastatic-malignant-neoplasm-to-the-lung, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, pain, sarcoma, smooth-muscle-tumor, uterine-corpus-sarcoma, uterine-fibroids, uterine-neoplasms.
Among the many pathways, these few ones have gauged particular interests from scientists studying Uterine Corpus Leiomyosarcoma, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Cycle Arrest, Cell Growth, Cell Motility, Cell Proliferation, Hemostasis, Hormone Secretion, Hypersensitivity, Inflammatory Response, Localization, Menopause, Menstruation, Mitosis, Muscle Contraction, Pathogenesis, Response To Paclitaxel, S Phase, Secretion
Quite a number of genes have been found to play important roles in Uterine Corpus Leiomyosarcoma, such as BCL2, CDKN1A, CFH, DES, ERBB2, ESR1, FH, KIT, LDLR, MID1, MTOR, PGR, PSMB9, TMEM37, TP53, TP63, VEGFA, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.